15,766 Shares in Vericel Corporation $VCEL Acquired by Inspire Investing LLC

Inspire Investing LLC bought a new position in shares of Vericel Corporation (NASDAQ:VCEL) during the third quarter, HoldingsChannel reports. The firm bought 15,766 shares of the biotechnology company’s stock, valued at approximately $633,000.

Several other hedge funds also recently made changes to their positions in VCEL. Kopp Family Office LLC increased its holdings in shares of Vericel by 0.6% in the 3rd quarter. Kopp Family Office LLC now owns 51,352 shares of the biotechnology company’s stock valued at $2,061,000 after acquiring an additional 299 shares during the last quarter. Juncture Wealth Strategies LLC lifted its stake in Vericel by 19.9% during the third quarter. Juncture Wealth Strategies LLC now owns 9,929 shares of the biotechnology company’s stock worth $399,000 after purchasing an additional 1,646 shares during the last quarter. Tidal Investments LLC bought a new position in Vericel during the second quarter worth $215,000. MCF Advisors LLC lifted its stake in Vericel by 293.0% during the second quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 583 shares during the last quarter. Finally, Scholtz & Company LLC acquired a new position in Vericel in the second quarter worth $2,287,000.

Analyst Upgrades and Downgrades

A number of research firms have commented on VCEL. Wall Street Zen raised shares of Vericel from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Truist Financial dropped their target price on shares of Vericel from $58.00 to $52.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. Weiss Ratings restated a “hold (c)” rating on shares of Vericel in a research report on Thursday. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Vericel in a research report on Tuesday, July 28th. Finally, Canaccord Genuity Group set a $60.00 price target on shares of Vericel in a report on Thursday, July 30th. Four analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $57.20.

Vericel Trading Down 6.2%

NASDAQ:VCEL opened at $40.26 on Friday. The firm has a market capitalization of $2.06 billion, a PE ratio of 85.66 and a beta of 1.02. The stock has a 50 day moving average of $40.58 and a 200-day moving average of $38.66. Vericel Corporation has a 52 week low of $28.95 and a 52 week high of $49.32.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Thursday, July 30th. The biotechnology company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. The business had revenue of $77.46 million for the quarter, compared to analysts’ expectations of $72.70 million. Vericel had a return on equity of 6.91% and a net margin of 7.91%. The business’s quarterly revenue was up 22.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.01) EPS. As a group, analysts predict that Vericel Corporation will post 0.54 EPS for the current fiscal year.

Vericel Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.